Introduction
Lexchin [
1] has described appropriate prescribing as ‘trying to maximise effectiveness, minimise risks and costs, and respecting service users’ choices [
1]. Of importance in judging prescribing appropriateness are what the service users wants or prefers as well as the scientific rationalisation [
2,
3].
Among people with substance misuse problems, their wider physical, psychological and social outcomes as well as their views may be particularly important when assessing the appropriateness of their medications. People with substance misuse problems often have complex circumstances encompassing health, social and economic problems [
4,
5], with service users attending specialist addiction clinics being more likely to have higher levels of dependence, multi-morbidities, functional impairment, social problems and use of multiple medications when compared with those who are not help-seeking [
6,
7]. These complex needs may influence prescribing decisions in this population [
7,
8]. For example, people with co-existing substance misuse problems and mental disorders may need higher doses or longer duration of treatment because they may have more severe and persistent symptoms or they may be more resistant to treatment [
9,
10].
Most of the published research on prescribing appropriateness has focused on the assessment of pharmacological appropriateness [
3]. Examples of measures used for assessing this include the medication appropriateness index (MAI) [
11] and the prescribing appropriateness index (PAI) [
12]. Moving beyond the medical perspective by considering service users’ preferences and context, introduces subjectivity into decision-making concerning appropriateness. Barber et al. [
3] have argued that the introduction of subjectivity is appropriate when making value judgments such as this.
Furthermore, given that intoxication and withdrawal symptoms of substances often mimic those of anxiety and mood disorders, an important clinical question relates to whether and when psychotropic medications could be used in treating the mental health symptoms of people with substance misuse problems [
13‐
15]. There is inconsistent evidence that psychotropic medications such as antidepressants and sedative/hypnotic drugs have beneficial effects on co-existing mental disorders in this population [
16‐
19].
It has been suggested that the service user’s perspective is particularly important and should be considered where there is a lack of adequate evidence or doubt about the best course of action [
20,
21]. In the UK, the NHS constitution states that the service it provides must reflect the needs and preferences of service users [
22]. Partnership with service users with open communication and consideration of their values and choices have been promoted in UK government policies and clinical guidance [
23,
24], with positive effects reported on satisfaction, medication adherence and well-being. Additional benefits described among those with substance misuse problems include increased personal control and reduced drug use [
25,
26]. Generally, service users want to be involved in decision-making concerning their treatment and medications [
26]. However, they often report feeling uninvolved in decision-making [
27]. A qualitative study that explored the experiences of service users in treatment for alcohol use disorders around their treatment needs and satisfaction while also comparing the experiences of those with and without co-morbid severe mental health symptoms (SMHS) found that those with comorbidity described a need for medications to relieve their psychological symptoms and were often dissatisfied when they were left out in the decision making process (including prescribing) [
27]. Although this study described the treatment needs of service users with comorbid SMHS, it was not focused on the appropriateness of prescribed psychotropic medications. No previous study has explored the views of people attending an addiction service concerning the appropriateness of psychotropic medications prescribed for their co-occurring mental illness. Consequently, this study was carried out to address this gap. Diagnoses of mental health illnesses and psychotropic medications were self-reported by service users.
This study was part of the first author’s (A.O) PhD programme. As a pharmacist, A.O has always had an interest in the quality of prescribing for service users, including those with substance misuse problems. A.O’s pharmacy training with emphasis on the use of medications for the management of substance misuse problems made her initially more inclined to view these disorders as brain diseases. Hence, A.O came with a medical perspective of substance misuse problems when she started her doctorate programme.
Aim
To explore the perspectives of service users in a specialist addiction service on the appropriateness of psychotropic medications prescribed for their co-existing mental health problems. Appropriateness was explored by assessing service users’ views concerning the following areas: their need for medications, medication effectiveness, medication changes, assessment and review.
Ethics approval
The study was approved by the University of York’s Research Governance Committee and the National Research Ethics Service (NRES) Committee Yorkshire & The Humber. Reference 12/YH/0325.
Discussion
This qualitative study aimed to explore service users’ views on the appropriateness of psychotropic medications prescribed for their co-existing mental health problems. Generally, service users described benefits from their medications (including those prescribed outside guideline recommendations) with trade-offs between their benefits and adverse effects. Service users had a sense of entitlement to being prescribed medications and seek to direct treatment decisions in line with their self-perceived needs. There were differing practices regarding the assessment and review of their medications.
Most service users described benefits from their medications, including service users who had been prescribed medications outside guideline recommendations. It was unclear whether all those prescribed outside guideline recommendations were aware of it because the interviews did not explore this issue due to its sensitive nature. Prescribing outside guideline recommendations (off-label prescribing) is common in psychiatry [
34] due to the limited number of clinical trials on patients with mental health problems (especially those with complex needs) [
35] as well as the non-availability of licensed medications for some psychiatric diagnoses [
36]. Off-label prescribing may therefore be necessary where there is a lack of an equally safe and effective licensed alternative, informed consent from the patient to be treated off-label, sufficient evidence in the literature to support the use of the drug as well as sufficient experience of using the medicine by the prescriber [
36].
Best practice recommendations including dosing and duration recommendations are usually established in clinical trials especially RCTs and where available, they serve as the foundation for clinical guidelines [
37,
38] including the BNF. Where there is no evidence from clinical trials, recommendations are based to a large extent on the opinions of experts who have substantial experience in that area [
39]. It may not be possible to directly extrapolate recommendations from guidelines on prescribing of psychotropic medications to people with substance misuse problems because most of the evidence from RCTs exclude them [
40,
41]. Changes in the neurochemistry of the reward pathways of the brain secondary to chronic use of substances may also affect prescribing decisions [
42] including dosing. Furthermore, consideration of the repercussions of relapse to substance use on the individual and society may well justify the need to sometimes prescribe outside guideline recommendations. Evidence from this study suggests that the appropriateness of prescribing is open to interpretation as some service users tended to view medications that improved their functioning as appropriate for them even when they were inappropriate by guideline standards.
While off-label prescribing may be clinically beneficial [
34] for people with substance misuse problems, it also carries clinical risks such as adverse effects. For instance, prescribing supra-BNF doses of antipsychotics carries a greater risk of unwanted side effects such as extrapyramidal side effects, sedation, tachycardia, weight gain, postural hypotension, and hyperprolactinaemia [
43]. The need for high doses of psychotropic medications such as anxiolytics/hypnotics may also expose the patient to the risk of dependence. In addition, people with substance misuse problems may exceed the recommended doses of these medications with the potential for overdosing [
44]. Although prescribers to achieve clinical benefit with minimal risk of harm, there is sometimes conflict between balancing effectiveness and risk [
45].
Service user involvement in their own care now represents a core value in the medical profession and UK National Health Service (NHS) [
24,
46]. The NHS constitution states that NHS services must reflect the needs and preferences of service users [
22]. However, there is sometimes conflict between physician-assessed need and what service users want, and how far prescribing should be determined by either of this remains an unresolved question [
2,
45]. Service users often have complex needs and risk issues that need to be taken into consideration in treatment decisions. Service users’ choices are challenging when people have substance misuse problems because they may be less than open about the reasons why they want medications. Given that service users may be at risk from medications [
13,
44,
47], prescribing decisions should be justified, and also be with due precautions that may involve limit setting, monitoring and behavioural rules in this population [
44]. Nevertheless, prescribers may be under considerably greater pressure to respond to the self-perceived needs of substance users compared with other patient groups. People with substance misuse problems appear to have a particularly strong sense of their own needs and seek to make their own choices about their prescriptions. This sense of empowerment may well influence prescribing decisions.
Furthermore, there should be effective communication between the prescriber and service user for the best decision to be arrived at [
48,
49]. The responses of service users in this study highlighted the fact that many of them valued this two-way communication. However, there were service users who described ineffective communication or dissatisfaction with their medications. This finding supports the results of a previous study [
27] where service users with co-existing severe mental health symptoms and alcohol use disorders valued being involved in treatment decisions and expressed the need for control over them. Service users in this previous study were often dissatisfied when decisions were made without their input. Service users usually report better satisfaction, medication adherence, improved well-being, increased personal control and reduction in drug use when clinicians partner with them in decision-making [
25,
26]. Health care strategies and UK guidance have also highlighted the importance of partnering with service users [
23,
24].
It has been suggested that prescribing may be used as a means of terminating difficult consultations [
50]. This may be more common in those with substance misuse problems, especially in time-pressured settings such as general practice [
51]. This suggests that where service users with substance misuse problems do have their health conditions reviewed, GPs may prescribe without careful assessment and prescriptions may therefore be inappropriate.
There is a growing trend to use mood-altering drugs including antidepressants to treat instances of human distress or emotional unhappiness [
52,
53]. It is possible that prescribing in response to life’s challenges and problems may be more common among people with substance misuse problems because of their high levels of vulnerability. Their situations are often complex with family disruptions, social and economic deprivation being prominent features [
5,
54]. The lifestyle of service users usually contributes to these problems and may result in demoralisation, a sense of distress and hopelessness [
44] which prescribers may be tempted to ‘fix’ with a pill. It is noteworthy that although medications are often very accessible they may not be the optimal solution. There is therefore the need for practitioners who are competent in delivering appropriate psychosocial therapies as protracted prescribing should be secondary to interventions geared to motivating people to make significant lifestyle changes. Integrated treatment by multidisciplinary teams with a focus on both the mental health disorder and substance misuse problem using a combination of pharmacotherapy and psychotherapy may also be needed. This approach has been shown to be more effective for the management of this comorbidity [
55,
56].
Repeat dispensing services, where repeat supply of medications are managed by the service user’s pharmacy of choice, was introduced in the NHS community pharmacy contractual framework in 2005 in order to manage repeat prescriptions more efficiently [
57]. Pharmacies are required to have appropriate governance in place for this service [
58]. Service users who are suitable for repeat dispensing include those with stable therapy, long-term conditions, multiple therapies and those who can self-manage seasonal conditions [
57]. This list is not exhaustive as other patient categories could be added based on clinical assessment. Repeat dispensing requires consent from the service user for their information to be shared between the dispensing and prescribing site. Recent evidence has shown that service users and prescribers value repeat prescribing and dispensing as it has the advantage of saving time, is convenient and also flexible [
59,
60]. Repeat prescribing further reduces the workload of prescribers. However, there have also been concerns around repeat dispensing in primary care with majority of respondents in the report by Petty [
59] stating that pharmacists never checked the items that were needed when they were ordered on behalf of the service users. The views expressed by some service users in this study clearly suggest that repeat prescribing and dispensing were not being regularly reviewed. Without on regular review of repeat medications, service users may end up being stuck on unnecessary medications and may become dependent medications that have such tendencies. Furthermore, it is also impossible to evaluate whether service users are still taking their medications with repeat prescribing. Consequently, lack of regular review of repeat prescriptions can lead to failure to detect and resolve drug-therapy problems as well as drug wastage [
61].
Over the course of this study and her doctorate programme, A.O’s engagement with service users, clinicians and the literature has broadened her views on substance misuse problems. She now considers substance misuse problems to be complex disorders involving social, psychological and behavioural mechanisms.
Strengths and limitations
To the knowledge of the authors, this is the first study to explore the views of service users attending a specialist addiction service on the appropriateness of psychotropic medications prescribed for their co-occurring mental health problems. Given that service users with substance misuse problems are difficult to recruit into research studies, a convenience sample of service users were interviewed. Consequently, the views of females and those with referral substances other than alcohol were under-represented in the interviews. Another limitation of this study is the fact that diagnoses and psychotropic medications were self-reported. There was no independent assessment of service users’ diagnoses. Most service users who took part in this study were referred from sources other than GPs to the addiction service and GP/referral notes were not available. Consequently, self-report was used as the source of information about diagnoses and prescribed medications. The findings may lack transferability to service users in other addiction services, especially given the changes that have occurred in substance misuse services in the UK. There has been an increase in the number of non-statutory and private sector providers of drug and alcohol services. Future research should involve multiple sites (including services run by the NHS and third sector organisations), to establish if the findings of this study are applicable. Furthermore, a single researcher collected study data and the researcher’s own perspectives may have affected interpretations that were made. However, the conduct, analysis and interpretation of data were overseen by two of the authors.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.